CUSIP 29337E102 · who reports it, how much, and how much it matters to them
38 of the 720 hedge fund managers we track reported shares of Enliven Therapeutics, Inc. (Nasdaq: ELVN) on Form 13F for 30 June 2026. Between them they reported USD 1.2bn. The largest position belongs to Orbimed Advisors, at USD 344m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Orbimed Advisors1 fund on PPLI.com | USD 344m | 6.4% |
| 2 | Polar Capital LLP26 funds on PPLI.com | USD 326m | 0.8% |
| 3 | Citadel Advisors32 funds on PPLI.com | USD 105m | 0.0% |
| 4 | Fairmount Funds Management2 funds on PPLI.com | USD 94m | 6.2% |
| 5 | Adage Capital Management1 fund on PPLI.com | USD 55m | 0.1% |
| 6 | Samlyn Capital8 funds on PPLI.com | USD 46m | 0.8% |
| 7 | Baker Bros. Advisors2 funds on PPLI.com | USD 46m | 0.2% |
| 8 | Balyasny Asset Management25 funds on PPLI.com | USD 31m | 0.0% |
| 9 | Marshall Wace LLP84 funds on PPLI.com | USD 27m | 0.0% |
| 10 | Logos Global Management1 fund on PPLI.com | USD 24m | 1.0% |
| 11 | Rock Springs Capital Management2 funds on PPLI.com | USD 24m | 1.2% |
| 12 | Millennium Management6 funds on PPLI.com | USD 21m | 0.0% |
| 13 | D. E. Shaw & Co.15 funds on PPLI.com | USD 16m | 0.0% |
| 14 | Deep Track Capital1 fund on PPLI.com | USD 11m | 0.2% |
| 15 | Cormorant Asset Management1 fund on PPLI.com | USD 7.6m | 0.4% |
| 16 | HighVista Strategies27 funds on PPLI.com | USD 7m | 1.6% |
| 17 | Eversept Partners3 funds on PPLI.com | USD 6.9m | 0.4% |
| 18 | Sphera Funds Management1 fund on PPLI.com | USD 5.7m | 0.7% |
| 19 | J. Goldman & Co.1 fund on PPLI.com | USD 5.7m | 0.1% |
| 20 | Cinctive Capital Management5 funds on PPLI.com | USD 5.5m | 0.2% |
| 21 | Exome Asset Management2 funds on PPLI.com | USD 5.1m | 3.1% |
| 22 | Artia Global Partners1 fund on PPLI.com | USD 3.7m | 0.7% |
| 23 | Great Point Partners2 funds on PPLI.com | USD 3.6m | 0.7% |
| 24 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 2.8m | 0.0% |
| 25 | Atom Investors1 fund on PPLI.com | USD 2.5m | 0.2% |
| 26 | Tudor Investment Corporation10 funds on PPLI.com | USD 2m | 0.0% |
| 27 | Boothbay Fund Management2 funds on PPLI.com | USD 2m | 0.0% |
| 28 | Brevan Howard Capital Management39 funds on PPLI.com | USD 1.7m | 0.0% |
| 29 | Engineers Gate Manager1 fund on PPLI.com | USD 1.5m | 0.0% |
| 30 | Two Sigma Investments35 funds on PPLI.com | USD 1.2m | 0.0% |
| 31 | Lighthouse Investment Partners190 funds on PPLI.com | USD 1m | 0.0% |
| 32 | Hudson Bay Capital Management8 funds on PPLI.com | USD 964,000 | 0.0% |
| 33 | Verdad Advisers6 funds on PPLI.com | USD 861,000 | 0.8% |
| 34 | Capstone Investment Advisors25 funds on PPLI.com | USD 537,000 | 0.0% |
| 35 | Persistent Asset Partners10 funds on PPLI.com | USD 479,000 | 0.1% |
| 36 | Aquatic Capital Management3 funds on PPLI.com | USD 426,000 | 0.0% |
| 37 | Squarepoint Ops7 funds on PPLI.com | USD 259,000 | 0.0% |
| 38 | The Quarry1 fund on PPLI.com | USD 205,000 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Orbimed Advisors | USD 344m | 6.4% |
| 2 | Fairmount Funds Management | USD 94m | 6.2% |
| 3 | Exome Asset Management | USD 5.1m | 3.1% |
| 4 | HighVista Strategies | USD 7m | 1.6% |
| 5 | Rock Springs Capital Management | USD 24m | 1.2% |
| 6 | Logos Global Management | USD 24m | 1.0% |
| 7 | Verdad Advisers | USD 861,000 | 0.8% |
| 8 | Polar Capital LLP | USD 326m | 0.8% |
| 9 | Samlyn Capital | USD 46m | 0.8% |
| 10 | Sphera Funds Management | USD 5.7m | 0.7% |
Enliven Therapeutics, Inc. trades under the symbol ELVN on the Nasdaq. Its CUSIP, the code used on Form 13F, is 29337E102.
38 of the 720 hedge fund managers PPLI.com tracks reported Enliven Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Orbimed Advisors (USD 344m), Polar Capital LLP (USD 326m), Citadel Advisors (USD 105m), Fairmount Funds Management (USD 94m) and Adage Capital Management (USD 55m).
38 managers in our coverage reported it, and between them they run 617 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Orbimed Advisors, where the position was 6.4% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Enliven Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.